Evidence map›Paper›PMID 41998206›Full record

ArticleBritish journal of cancer2026

Kidney-specific HIF-1α-dependent ARL10/miR-1271-5p overexpression in clear cell renal cell carcinoma.

Patric M Page, Tania Laperrière, Sonia A Dastous, Sophie E Landry, Patrick O Richard, Michel Pavic, Sandra Turcotte

Abstract read
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patric M PageDepartment of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada.
Tania LaperrièreDepartment of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada.
Sonia A DastousDepartment of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada.
Sophie E LandryDepartment of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada.
Patrick O RichardDepartment of Urology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.
Michel PavicInstitut de recherche sur le cancer de l'Université de Sherbrooke, Sherbrooke, QC, Canada.
Sandra TurcotteDepartment of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada. Sandra.turcotte@umoncton.ca.ORCID http://orcid.org/0000-0002-7980-8736

Funding

Canadian Cancer Society Research Institute (Société Canadienne du Cancer) 706199Kidney Foundation of Canada (La Fondation canadienne du rein) 180017
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is primarily driven by chromosome 3p loss and inactivation of the von Hippel-Lindau (VHL) gene, which is frequently accompanied by chromosome 5q gain. However, the oncogenic contribution of 5q remains unclear. This study examines how 5q gain affects the expression of microRNAs implicated in ccRCC.

methodsBioinformatic analyses were conducted to evaluate miRNAs associated with 5q gain and 3p loss. RT-qPCR validation was performed in tumour tissues and patient plasma. Mechanistic investigations integrated open-source ChIP-seq datasets and luciferase reporter assays.

resultsmiR-1271-5p overexpression was significantly associated with both 5q gain and 3p loss and strongly correlated with its host gene, ARL10. RT-qPCR confirmed elevated levels of miR-1271-5p and ARL10 in ccRCC tumours and increased circulating miR-1271-5p in patient plasma. Mechanistically, these upregulations resulted from VHL loss and subsequent HIFα stabilisation. ChIP-seq datasets and luciferase assays demonstrated that HIF-1α, but not HIF-2α, directly binds within the intragenic region of ARL10. Importantly, this regulatory mechanism was specific to kidney cells.

conclusionsCoordinated upregulation of miR-1271-5p and ARL10 reflects key genomic events in ccRCC and is driven by kidney-specific HIF-1a activity. Our findings suggest their promise for early detection and disease monitoring.

Indexed as

ADP-Ribosylation FactorsCarcinoma, Renal CellHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsMicroRNAsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansVon Hippel-Lindau Tumor Suppressor ProteinADP-Ribosylation FactorsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID41998206
PMCPMC13310816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.